FONT-SIZE Plus   Neg

Valeant Pharmaceuticals Agrees To Buy Ophthalmic Biotechnology Company EyeTech

Specialty pharmaceutical company Valeant Pharmaceutical International Inc (VRX,VRX.TO) Monday announced that it has agreed to acquire Eyetech Inc., a privately-owned ophthalmic biotechnology company dedicated to the treatment of sight-threatening diseases of the retina, for an upfront payment and potential future milestones that total significantly less than two times sales.

Valeant stated that the transaction, which is subject to customary closing conditions, is expected to close this week. The transaction is expected to be immediately accretive.

Eyetech currently markets Macugen in the United States, the first anti-VEGF inhibitor approved for the treatment of wet age-related macular degeneration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Software giant Microsoft Corp. (MSFT), Tuesday reported a profit for the first quarter that trumped analysts' estimates, as CEO Satya Nadella's strategy seems to be working reflected by strong growth in cloud business. Microsoft stock spiked up over 5 percent in after hours trading. Redmond, Washington-based... In order to make Facebook more user-friendly, the social media giant introduced a few attractive new features. Recommendation tool, call-to-action buttons, and new section pages are expected to attract more users in a world where there are more mobiles than human beings. Starbucks Coffee Co. said Thursday that it plans to open a Reserve Roastery in Japan in 2018. This will be the coffee giant's fourth Roastery location globally. The new location will be located in Tokyo's upscale Nakameguro district, known for its exclusive boutiques and art galleries.
comments powered by Disqus
Follow RTT